Listen on the go
CORRECT!
Next question
touchONCOLOGY touchONCOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Ovarian Cancer

    An Introduction to Ovarian Cancer

    Before 2016 the prognosis for patients with ovarian cancer was poor, and treatment options were limited. However, the introduction of bevacizumab followed by PARP inhibitors transformed outcomes in patients with BRCA1/2 mutation. Anti-angiogenic agents, immuno-oncology agents, combinations of these agents and hyperthermic intraperitoneal chemotherapy are currently being investigated and show promise for the future.

    Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape.

    Ovarian Cancer Content

    Gynaecological Cancers, Ovarian Cancer
    Developed by Touch
    Niraparib as first-line maintenance treatment in ovarian cancer
    Antonio González Martín Watch Time: 8.37 minutes

    The phase III PRIMA/ENGOT-OV26/GOG-3012 trial evaluated the efficacy of niraparib as a first-line maintenance treatment for patients with advanced ovarian cancer who responded to platinum-based chemotherapy. In this final analysis, no significant difference in overall survival was observed between niraparib and placebo in the overall or homologous recombination-deficient (HRd) populations. However, long-term progression-free survival and […]

    Gynaecological Cancers, Ovarian Cancer
    Developed by Touch
    Addition of nivolumab to rucaparib did not improve clinical outcomes in newly diagnosed, advanced, high-grade ovarian cancer
    Bradley J Monk Watch Time: 9 mins

    The ATHENA trial evaluated the effectiveness of rucaparib (RUCA) monotherapy (MONO) and rucaparib combined with nivolumab (NIVO) (COMBO) in patients with advanced high-grade ovarian cancer (AHGOC). In the MONO arm, rucaparib showed sustained progression-free survival (PFS) of 20.2 months after first-line treatment. However, the COMBO arm did not improve PFS, with median PFS being shorter […]

    Gynaecological Cancers, Ovarian Cancer
    Key insights in gynecological malignancies: BrUOG 354, AGO-OVAR 2.29/ENGOT-ov34, KEYVIBE-005, CARACO
    Domenica Lorusso Watch Time: 6 mins

    To further understand the key developments and research presented in the field of gynaecological oncology at ASCO 2024, we spoke with Dr. Domenica Lorusso, Professor of Obstetrics and Gynaecology at Humanitas University of Milan, Italy. In this interview, Dr. Lorusso discusses the findings from the BrUOG 354 (NCT03355976), AGO-OVAR 2.29/ENGOT-ov34 (NCT03353831), KEYVIBE-005 (NCT05007106), and CARACO (NCT01218490) trials, offering her valuable insights into the potential impact these results could have on clinical practice.

    Gynaecological Cancers, Ovarian Cancer
    Clinical advancements and key presentations: ESGO 2024

    Highlights from ESGO 2024, featuring the latest data and insights presented at the meeting.

    Ovarian Cancer, Gynaecological Cancers
    Watch Time: 53 mins
    touchCONGRESS
    PARP inhibitors in ovarian cancer: Clinical updates from SGO 2023
    Dr Domenica Lorusso, Dr Susana Banerjee, Prof. Frederik Marmé

    Watch this activity exploring recent developments on the use of PARP inhibitors in ovarian cancer, covering first-line maintenance therapy, selection and sequencing implications, and future directions including emerging neoadjuvant and combination regimens. Filmed following the SGO Annual Meeting 2023.

    Learning objectives
    Learning Objectives
    • Describe the latest efficacy data for PARP inhibitors in the treatment of ovarian cancer
    • Recall the latest safety data for PARP inhibitors in the treatment of ovarian cancer
    • Evaluate how the latest data may impact the use of PARP inhibitors in clinical practice
    Ovarian Cancer, Gynaecological Cancers
    Watch Time: 57 mins
    touchCONGRESS
    PARP inhibitors as first-line maintenance therapy in ovarian cancer: How can data from ESGO 2022 guide clinical practice?
    Prof. Jonathan Ledermann, Dr David Tan, Dr Anna Tinker

    Watch this two-part activity exploring the latest data on the use of PARP inhibitors in first-line maintenance therapy in ovarian cancer. Filmed following the ESGO European Congress on Gynaecological Oncology 2022. Part 1: Watch gynaecological cancer expert Prof. Jonathan Ledermann review key data from ESGO 2022 Watch Now Part 2: Watch leading experts consider what these data may mean for global and regional practice Select An Interview

    Learning objectives
    Learning Objectives
    • Outline the latest clinical trial data for PARP inhibitors in the first-line maintenance setting for advanced ovarian cancer
    • Describe real-world data on the use of PARP inhibitors in the first-line maintenance setting for advanced ovarian cancer
    • Discuss how the clinical trial and real-world data may impact the use of PARP inhibitors in clinical practice
    Ovarian Cancer
    Developed by Touch
    Paul DiSilvestro, ESMO 2022: SOLO1/GOG-3004 trial – Olaparib for the treatment of advanced ovarian cancer – Overall survival findings at 7 years
    Watch Time: 5 mins

    The Phase III SOLO1/GOG-3004 trial (NCT01844986), investigated maintenance olaparib, which provided sustained benefit beyond the end of treatment in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation. Prof. Paul DiSilvestro (Brown University, Providence, RI, USA) joins touchONCOLOGY to discuss the efficacy and safety of maintenance olaparib, and overall survival findings at 7 years. […]

    touchROUNDTABLE
    Clinical decision making in advanced ovarian and advanced/recurrent endometrial cancers
    For HCPs in: Europe
    View Time: 62 mins Sponsored content

    Promotional content from GSK. Watch leading experts Jalid Sehouli, Nicole Concin, Shibani Nicum and Lynn Buckley discuss how to individualise clinical decision making for gynaecological cancers.

    Dostarlimab ▼ Prescribing Information (GB)

    PM-GBL-AOU-WBAN-220001
    Date of Preparation: July 2022
    Ovarian Cancer, Gynaecological Cancers
    Watch Time: 35 mins
    touchIN CONVERSATION
    Maximizing the potential of PARP inhibitors as first-line maintenance therapy in ovarian cancer: Improving patient identification and treatment selection
    Prof. Nicoletta Colombo, Dr Natalia R Gómez-Hidalgo

    Watch ovarian cancer experts discuss key considerations for optimizing patient outcomes with PARP inhibitors as first-line maintenance therapy.

    Learning objectives
    Learning Objectives
    • Discuss the rationale for using PARP inhibitors in the first-line maintenance treatment of advanced ovarian cancer
    • Identify patients who may benefit from a PARP inhibitor in the first-line maintenance setting
    • Describe the key factors that can inform selection of the most appropriate PARP inhibitor for each patient
    In Partnership with...
    Useful Links:
    About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
    Connect With Us:

    Other websites from Touch Medical Media:

    touchONCOLOGY
    touchOPHTHALMOLOGY
    touchENDOCRINOLOGY
    touchNEUROLOGY
    touchCARDIO
    touchRESPIRATORY
    touchIMMUNOLOGY
    touchINFECTIOUS DISEASES
    touchHAEMATOLOGY
    touchDERMATOLOGY

    Copyright® 2024 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

    touchONCOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup